Medicin og biovidenskab
Glucagon-Like Peptide-1 Receptor
66%
Glucagon-Like Peptide 1
59%
Exenatide
55%
Toxicology
49%
Pharmacokinetics
38%
Type 2 Diabetes Mellitus
38%
Safety
23%
Tachyphylaxis
14%
Liraglutide
14%
Injection Site Reaction
14%
Expert Testimony
10%
United States Food and Drug Administration
10%
Pancreatitis
9%
Action Potentials
9%
Antibody Formation
9%
Kinetics
7%
Obesity
7%
Glucose
6%
Therapeutics
3%
Neoplasms
3%
Kemiske forbindelser
Glucagon-Like Peptide-1 Receptor Agonist
100%
Agonist
48%
Safety
43%
Pharmacokinetics
38%
Liraglutide
24%
Exendin-4
22%
Twice Daily
19%
Agent Interacting With Transmitter, Hormone or Drug Receptor
14%
Clearance
13%
Glucose
9%
Reduction
5%